Galen, the privately-owned pharmaceutical sales, and marketing company, has today announced the launch of their TYR EASY Tablets, the first solid-dose protein substitute option for tyrosinaemia, into the UK market.
Galen’s TYR EASY Tablets are designed to support dietary management for patients over the age of 8 with tyrosinaemia (TYR), giving them more choice of protein substitutes which best fit with their day-to-day needs.
Galen entered into the medical nutrition market in early 2020 and offer products for a range of metabolic disorders including Phenylketonuria (PKU).
Dr Sarah Dolan, Galen Medical Nutrition’s Commercial Manager and representative in the UK and Ireland, said: "Galens primary focus is always to support patients with their medical nutrition requirements. We are pleased to launch TYR EASY Tablets to the UK market. We know that finding the right products and supplements can be difficult for people with metabolic disorders and we work hard to develop new products that will give patients greater choice and support."
TYR EASY Tablets are the first of seven new metabolic products currently in development for a mix of the UK market and Nordics markets and are expected to be available over the next two years.
"We are delighted to be able to extend our reach and support to more metabolic disease areas with Galen’s high quality medical nutrition products in the next 24 months."
The expansion of Galen’s medical nutrition portfolio will build on solid-dose protein substitute expertise and enhance patient choice across a range of metabolic disorders including Homocystinuria (HCU), Urea Cycle Disorder (UCD) and Maple Syrup Urine Disease (MSUD).
Galen Medical Nutrition is committed to bringing innovation, quality, and customer focus to people with metabolic disorders.
